Havana, May 26 .- The World Health Organization (WHO) reported on Monday that the executive group of the "Solidarity Trial", which is seeking treatments for Covid-19, decided to temporarily suspend clinical trials with hydroxychloroquine .
According to the WHO, a scientific observational study published last Friday by The Lancet on the effects of these drugs in new coronavirus-positive patients who have been hospitalized and received the drug, when given alone or with a macrolide, had a rate of higher mortality, reported WHO director during his regular press conference.
He stated that the executive group, representing 10 of the countries participating in the trial, agreed to do a comprehensive analysis and critical evaluation of all the evidence available worldwide on the use of hydroxychloroquine.
The review will consider the data collected so far, and in particular the available randomized data, to properly assess the potential benefits and harms of this drug, the director said.
Although a temporary pause of the hydroxychloroquine arm has been implemented within the global clinical trial, the other planned drugs will continue to be tested.
In closing, Adhanom Gebreyesus reiterated that these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria, and stated that the WHO, as part of the response to the pandemic, will continue to work aggressively in research and development, and will provide necessary updates as more information becomes available. (Text and Photo: ACN)